Assertio Holdings, Inc. ("Assertio" or the "Company") (Nasdaq: ASRT) today announced that results of a clinical trial ...

Shilpa Medicare targets US approval of 5-HT3 receptor antiemetic for chemotherapy-induced nausea and vomiting: Our Bureau, Bengaluru Friday, January 9, 2026, 12:15 Hrs [IST] Shilp ...

As of Friday, January 09, Heron Therapeutics, Inc.’s HRTX share price has surged by 18.11%, which has investors questioning ...

The New Year brings with it a set of new laws in New York state that will impact health care services for cancer patients, ...

Heron Therapeutics, Inc. (Nasdaq: HRTX) ('Heron” or the 'Company”), a commercial-stage biotechnology company, today announced ...

As they waited Wednesday night for another of his passages that would strike a real chord in them — this one unfortunately like no other — some of the assembled police officers thought of another one ...

Potential blockbusters and root-cause treatments from Eli Lilly, Merck, Takeda and others could get a regulatory nod this ...

Understand the role of reproductive biotech in overcoming biological limits in fertility treatments and enhancing success ...

Merck begins phase 3 KANDLELIT-007 trial of calderasib in combo Keytruda QLEX in certain patients with advanced NSCLC: Rahway, New Jersey Friday, January 9, 2026, 15:00 Hrs [IST] ...

HERCESSI(TM) becomes one of two trastuzumab biosimilars on preferred formulary placement, expanding patient access to more affordable HER2-targeted oncology therapies RALEIGH, N.C., Jan. 5, 2026 ...

Eli Lilly has dominated headlines in recent months, recently taking the crown as the most valuable company in the biopharma industry by market cap. | Two investigational cardiometabolic drugs from Eli ...

Driven by a paradigm shift to curative early-stage interventions and surging ADC demand, the market offers massive upside.